Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, TRI, FVT

OrphoMed to Present at the 2018 BIO CEO & Investor Conference


SAN FRANCISCO, Jan. 31, 2018 /PRNewswire/ -- OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, announced today that Nikhilesh N. Singh, Ph.D., President and Chief Executive Officer, will present at the 20th Annual BIO CEO & Investor Conference, being held February 12-13, 2018, in New York City.

 (PRNewsfoto/OrphoMed, Inc.)

Presentation Date: February 12, 2018

Time: 9:30 a.m. EST

Location: New York Marriott Marquis, Gilbert Room, 4th Floor

A copy of the presentation will be available at www.orphomed.com.

About OrphoMed, Inc.
OrphoMed is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class dimer therapeutics for patients with gastrointestinal disorders. Leveraging its proprietary dimer platform technology, OrphoMed is advancing ORP-101, a potential best-in-class buprenorphine dimer in clinical development for the treatment of IBS-D, and its pipeline of additional dimer conjugates. For more information please visit www.orphomed.com.

 

SOURCE OrphoMed, Inc.


These press releases may also interest you

at 09:55
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that it has been named an Edison Award Winner in the 2024 Edison Awards, for the second year in a row. Viz PE with right ventricle/left ventricle...

at 09:50
The "Targeted Sequencing Market - A Global and Regional Analysis: Focus on Application, Product Type, Target Enrichment Methods, Type of Target Capture, End User, and Region - Analysis and Forecast, 2024-2033" report has been added to...

at 09:43
Discover new ways to make your skin BLOOM! Beekman 1802's top selling skin barrier-building formula, Bloom Cream Daily Face Moisturizer, is now available in two NEW formats that will make blooming even better! Introducing the Bloom Cream in a Tube...

at 09:00
ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of A5374, a phase 1/2a study evaluating the safety, tolerability, and antiviral effect of a novel combination regimen that includes...

at 09:00
PureTalk, a nationwide cell phone service provider offering premium wireless service at a fair price on the nation's most dependable 5G network, today celebrates over $100,000 customer donations to the America's Warrior Partnership (AWP). Since...

at 09:00
Amid growing concerns about a medical crisis as a result of acute conflict between the government...



News published on and distributed by: